

Amendments To The Claims

1. (Amended) A method of treating a central nervous system (CNS) lymphoma comprising the step of administering to a subject diagnosed with said CNS lymphoma a therapeutically effective amount of an anti-CD20 antibody or fragment thereof.

2. (Canceled).

3. (Original) The method of claim 1, wherein the CNS lymphoma is selected from the group consisting of: primary CNS lymphoma (PCNSL), leptomeningeal metastases (LM), or Hodgkin's disease with CNS involvement.

4. (Original) The method of claim 3, wherein the CNS lymphoma is LM and wherein the anti-CD20 antibody or fragment thereof is administered in combination with cytarabine and thiotepa or methotrexate and ¹¹¹In-diethylenetriamine pentaacetic acid.

5. (Original) The method of claim 1, wherein the anti-CD20 antibody fragment is selected from the group consisting of Fab, Fab' and F(ab')₂.

6. (Canceled).

7. (Original) The method of claim 1, wherein the anti-CD20 antibody is a human antibody, humanized, bispecific or chimeric.

8-50. (Canceled).

51. (New) A method of treating a central nervous system (CNS) lymphoma comprising the step of administering to a subject diagnosed with said CNS lymphoma a therapeutically effective amount of an anti-CD20 antibody or fragment thereof, whereby growth of a CNS lymphoma is reduced.

52. (New) The method of claim 51, wherein the CNS lymphoma is selected from the group consisting of: primary CNS lymphoma (PCNSL), leptomeningeal metastases (LM), or Hodgkin's disease with CNS involvement.

53. (New) The method of claim 52, wherein the CNS lymphoma is LM and wherein the anti-CD20 antibody or fragment thereof is administered in combination with

DO NOT ENTER. GW 8/15/03

cytarabine and thiotepa or methotrexate and ¹¹¹In-diethylenetriamine pentaacetic acid.

54. (New) The method of claim 51, wherein the anti-CD20 antibody fragment is selected from the group consisting of Fab, Fab' and F(ab')₂.

55. (New) The method of claim 51, wherein the anti-CD20 antibody is a human antibody, humanized, bispecific or chimeric.

56. (New) A method of treating a central nervous system (CNS) lymphoma comprising the step of administering to a subject diagnosed with said CNS lymphoma a therapeutically effective amount of an anti-CD20 antibody or fragment thereof, whereby levels of the anti-CD20 antibody are greater in cerebrospinal fluid (CSF) than in serum.

57. (New) The method of claim 56, wherein the CNS lymphoma is selected from the group consisting of: primary CNS lymphoma (PCNSL), leptomeningeal metastases (LM), or Hodgkin's disease with CNS involvement.

58. (New) The method of claim 57, wherein the CNS lymphoma is LM and wherein the anti-CD20 antibody or fragment thereof is administered in combination with cytarabine and thiotepa or methotrexate and ¹¹¹In-diethylenetriamine pentaacetic acid.

59. (New) The method of claim 56, wherein the anti-CD20 antibody fragment is selected from the group consisting of Fab, Fab' and F(ab')₂.

60. (New) The method of claim 56, wherein the anti-CD20 antibody is a human antibody, humanized, bispecific or chimeric.